当前位置: X-MOL 学术Neuropathol. Appl. Neurobiol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Advanced molecular pathology for rare tumours: A national feasibility study and model for centralised medulloblastoma diagnostics
Neuropathology and Applied Neurobiology ( IF 4.0 ) Pub Date : 2021-04-07 , DOI: 10.1111/nan.12716
Stephen Crosier 1, 2 , Debbie Hicks 1 , Edward C Schwalbe 1, 3 , Daniel Williamson 1 , Sarah Leigh Nicholson 2 , Amanda Smith 1 , Janet C Lindsey 1 , Antony Michalski 4 , Barry Pizer 5 , Simon Bailey 1 , Nick Bown 2 , Gavin Cuthbert 2 , Stephen B Wharton 6 , Thomas S Jacques 7 , Abhijit Joshi 2 , Steven C Clifford 1
Affiliation  

Application of advanced molecular pathology in rare tumours is hindered by low sample numbers, access to specialised expertise/technologies and tissue/assay QC and rapid reporting requirements. We assessed the feasibility of co-ordinated real-time centralised pathology review (CPR), encompassing molecular diagnostics and contemporary genomics (RNA-seq/DNA methylation-array).

中文翻译:

罕见肿瘤的高级分子病理学:集中髓母细胞瘤诊断的国家可行性研究和模型

先进分子病理学在罕见肿瘤中的应用受到样本数量少、获得专业知识/技术和组织/分析 QC 和快速报告要求的阻碍。我们评估了协调实时集中病理学审查 (CPR) 的可行性,包括分子诊断和当代基因组学(RNA-seq/DNA 甲基化阵列)。
更新日期:2021-04-07
down
wechat
bug